American scientists from the University of Tulein have found that the drug used against melanoma and other types of cancer may be the key to ipilimumab’s idiopathic pulmonary fibrosis (ILF) treatment – a cured disease that caused a deadly disease of 50% of patients for three years. Results published scientifically broadcasting Journal of Clinical Research (JCI).
With IFL, “old” lung cells accumulate and cause scarring. However, the immune system does not remove them due to excess CTLA4 protein that blocks T cells.
The team found that ipilimumab pressed CTLA4 and allowed immunity to clean the damaged cells. Mouse tests showed that the drug reduced fibrosis by 40-60% and restored the lung tissue.
According to the researchers, they found the first effective method that rejected the scarring process.
In addition, the approach can be used for other diseases such as alzheimer’s or heart failure.
Personnel tests will start in 2024-2025. If the method is confirmed, this will be a breakthrough in the treatment of 3 million patients with ILF worldwide.
Previously, scientists learned Causes of the development of unramed lung fibrosis.
What are you thinking?
Source: Gazeta
Barbara Dickson is a seasoned writer for “Social Bites”. She keeps readers informed on the latest news and trends, providing in-depth coverage and analysis on a variety of topics.